Search
Rabeximod
go.drugbank.com/drugs/DB05772InvestigationalRabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
MIP-1095 I-131
go.drugbank.com/drugs/DB14978InvestigationalMIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).
INCB13739
go.drugbank.com/drugs/DB05064InvestigationalINCB13739 is developed as a new treatment for type 2 diabetes. … It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes
VB2-011
go.drugbank.com/drugs/DB05411ExperimentalVB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. … This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).
Trandolaprilat
go.drugbank.com/drugs/DB14209ExperimentalThe active metabolite of the prodrug Trandolapril.
Categories: Agents Acting on the Renin-Angiotensin SystemThenoyltrifluoroacetone
go.drugbank.com/drugs/DB04795ExperimentalThenoyltrifluoroacetone is a chelating agent and inhibitor of cellular respiration.
Categories: Compounds used in a research, industrial, or household settingTolu balsam
go.drugbank.com/drugs/DB11223InvestigationalCategories: Compounds used in a research, industrial, or household settingBarbexaclone
go.drugbank.com/drugs/DB09001ExperimentalThese reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials. … Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital.
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalThe drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor. … It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003
Rebaudioside A
go.drugbank.com/drugs/DB15136InvestigationalRebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).
Synonyms: Rebaudioside A